Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial
Candoni, Anna, Papayannidis, Cristina, Martinelli, Giovanni, Simeone, Erica, Gottardi, Michele, Iacobucci, Ilaria, Gherlinzoni, Filippo, Visani, Giuseppe, Baccarani, Michele, Fanin, RenatoLangue:
english
Journal:
American Journal of Hematology
DOI:
10.1002/ajh.25057
Date:
February, 2018
Fichier:
PDF, 721 KB
english, 2018